API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2010
(Rs. In Lacs except per share data)
PARTICULARS Quarter Ended Quarter Ended Nine Months Ended Nine Months Ended Year ended
31st Dec 2010 31st Dec 2009 31st Dec 2010 31st Dec 2009 31st Mar 2010
Gross Sales / Income from operations 14,181 12,250 37,589 36,474 49,695
Less : Excise Duty & Sales Tax 577 547 1,892 1,817 2,553
1. (a) Net Sales / Income from operations 13,604 11,703 35,697 34,657 47,142
(b) Other Operating Income
2. Expenditure
(a). (Increase) / Decrease in stock in trade (707) 81 (1,971) (23) 376
(b). Consumption of raw materials. 7,600 5,811 19,705 17,454 23,179
(c). Purchase of Traded Goods 2,621 2,190 6,572 5,944 8,202
(d). Employees cost 409 345 1,214 1,012 1,362
(e). Depreciation 393 341 1,131 1,004 1,352
(f). Other expenditure 2,155 1,797 5,701 4,957 6,859
(g). Total Expenditure 12,471 10,565 32,352 30,347 41,330
3. Profit from Operating before Other Income 1,133 1,139 3,345 4,310 5,811
4. Other Income 2 3 7 34 45
5. Profit before Interest & Exceptional Items 1,135 1,142 3,352 4,344 5,856
6. Interest 377 311 939 1,143 1,474
7. Profit after Interest but before Exceptional Items 758 831 2,413 3,201 4,382
8. Exceptional Items - - - - -
9. Profit from Ordinary Activities before Tax 758 831 2,413 3,201 4,382
10. Tax Expenses (Includes) 256 351 795 1,314 1,772
(a). Provision for Taxation 184 284 586 1,111 1,502
(b). Provision for Deffered Taxation 72 67 209 203 270
11. Net profit from ordinary Activities after Tax 502 480 1,618 1,887 2,610
12. Extraodinary Item (net of tax expenses ) - - - - -
13. Net Profit for the period 502 480 1,618 1,887 2,610
14. Paid-up Equity Share Capital of Rs.10/- each. 1,211 1,211 1,211 1,211 1,211
15. Reserves & Surplus (excluding revaluation reserves) - - - - 12,898
16. Basic & Diluted E P S (in Rs.) 4.15 3.96 13.36 15.58 22.08
17. Public Shareholding
-Number of Shares 5638133 6051226 5638133 6051226 6051226
-Percentage of Total Shareholding 46.56 49.97 46.56 49.97 49.97
18. Promoters & Promoter Group
Shareholding
(a) Pledged/Encumbered
- Number of Shares NIL NIL NIL NIL NIL
-Percentage of shares( as a percentage of the NIL NIL NIL NIL NIL
total shareholding of promoter and promoter group)
-Percentage of shares( as a percentage of NIL NIL NIL NIL NIL
total sharecapital of the Company)
b) Non-encumbered
- Number of Shares 6470417 6057324 6470417 6057324 6057324
-Percentage of shares( as a percentage of 100 100 100 100 100
total shareholding of promoter and promoter group)
-Percentage of shares( as a percentage of 53.44 50.03 53.44 50.03 50.03
total sharecapital of the Company)

Notes :


1. The above results for the quarter and nine months ended 31st December,2010 have been reviewed by the Audit
Committee and approved by the Board of Directors in their Meeting held on 2nd February,2011.


2. Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement
as per AS - 17 'Segment Reporting' is not attracted.


3. The Board of Directors have declared Interim Dividend of Rs.2.50 paise per equity share of Rs.10/- each
( 25%) amounting to Rs.3,02,71,375 and 8th February,2011 has been fixed as record date for the payment of the said
interim dividend.


4. Details of Investors Complaints received for the quarter ended 31st December,2010
Beginning:- 1 Received:-4 Resolved:-3 Pending:- 2


5. Figures for the previous period have been regrouped or rearranged wherever necessary.

For and on behalf of the Board
FOR AARTI DRUGS LIMITED
Place : Mumbai
Harshit M Savla
DATE : 2nd February, 2011
(Jt. Managing Director)
 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech